Skip to main content

Electrophysiology CONVERGE Post-Approval Study (PAS)

Status: Closed to Enrollment

Study Details

View study details on clinicaltrials.gov.

Locations

  • San Francisco
  • Oakland
  • Burlingame

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.

Please contact: Milena.Ferreira@sutterhealth.org about study.

Christopher Woods, M.D.
Christopher Woods, M.D.
Principal investigator
View Profile

Co-investigator

Amir Schricker

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?